These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25675301)

  • 21. Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib.
    Zucchetti M; Bonezzi K; Frapolli R; Sala F; Borsotti P; Zangarini M; Cvitkovic E; Noel K; Ubezio P; Giavazzi R; D'Incalci M; Taraboletti G
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):879-87. PubMed ID: 23978989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy.
    Czabanka M; Vinci M; Heppner F; Ullrich A; Vajkoczy P
    Int J Cancer; 2009 Mar; 124(6):1293-300. PubMed ID: 19101989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determinants for in vivo antitumor effect of angiogenesis inhibitor SU5416 formulated in PEGylated emulsion.
    Ogawara K; Abe S; Un K; Yoshizawa Y; Kimura T; Higaki K
    J Pharm Sci; 2014 Aug; 103(8):2464-9. PubMed ID: 24985750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sunitinib effects on the radiation response of endothelial and breast tumor cells.
    El Kaffas A; Al-Mahrouki A; Tran WT; Giles A; Czarnota GJ
    Microvasc Res; 2014 Mar; 92():1-9. PubMed ID: 24215790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
    Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
    Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice.
    Gu Y; Zhao W; Meng F; Qu B; Zhu X; Sun Y; Shu Y; Xu Q
    Clin Immunol; 2010 Apr; 135(1):55-62. PubMed ID: 20015695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1.
    Di Desidero T; Fioravanti A; Orlandi P; Canu B; Giannini R; Borrelli N; Man S; Xu P; Fontanini G; Basolo F; Kerbel RS; Francia G; Danesi R; Bocci G
    J Clin Endocrinol Metab; 2013 Sep; 98(9):E1465-73. PubMed ID: 23969186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib.
    Baccala A; Hedgepeth R; Kaouk J; Magi-Galluzzi C; Gilligan T; Fergany A
    Int J Urol; 2007 Dec; 14(12):1095-7; discussion 1097. PubMed ID: 18036049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
    Saltz LB; Rosen LS; Marshall JL; Belt RJ; Hurwitz HI; Eckhardt SG; Bergsland EK; Haller DG; Lockhart AC; Rocha Lima CM; Huang X; DePrimo SE; Chow-Maneval E; Chao RC; Lenz HJ
    J Clin Oncol; 2007 Oct; 25(30):4793-9. PubMed ID: 17947727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway.
    Ping SY; Wu CL; Yu DS
    Urol Oncol; 2012 Sep; 30(5):652-9. PubMed ID: 20884251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
    Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
    Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors.
    Levashova Z; Backer M; Hamby CV; Pizzonia J; Backer JM; Blankenberg FG
    J Nucl Med; 2010 Jun; 51(6):959-66. PubMed ID: 20484434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment.
    Nagengast WB; Lub-de Hooge MN; Oosting SF; den Dunnen WF; Warnders FJ; Brouwers AH; de Jong JR; Price PM; Hollema H; Hospers GA; Elsinga PH; Hesselink JW; Gietema JA; de Vries EG
    Cancer Res; 2011 Jan; 71(1):143-53. PubMed ID: 21084271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Establishment of a novel experimental model of human angiosarcoma and a VEGF-targeting therapeutic experiment.
    Hoshina D; Abe R; Yoshioka N; Saito N; Hata H; Fujita Y; Aoyagi S; Shimizu H
    J Dermatol Sci; 2013 May; 70(2):116-22. PubMed ID: 23522954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors.
    Voce P; D'Agostino M; Moretti S; Sponziello M; Rhoden K; Calcinaro F; Tamburrano G; Tallini G; Puxeddu E; Filetti S; Russo D; Durante C
    Oncol Rep; 2011 Nov; 26(5):1075-80. PubMed ID: 21850379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
    Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N
    J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sunitinib inhibits the phosphorylation of platelet-derived growth factor receptor β in the skin of mice with scleroderma-like features and prevents the development of the disease.
    Kavian N; Servettaz A; Marut W; Nicco C; Chéreau C; Weill B; Batteux F
    Arthritis Rheum; 2012 Jun; 64(6):1990-2000. PubMed ID: 22213155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
    Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
    Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.